Shots:
- The first patient is dosed in P-III (HERTHENA-Breast04) trial (n=~1000) of patritumab deruxtecan (HER3-DXd; 5.6mg/kg) vs CT/Enhertu for unresectable LA/M, HR+, HER2- breast cancer after progression on endocrine & CDK4/6 inhibitor therapy in either adjuvant or 1L metastatic settings
- HERTHENA-Breast04 was initiated based on findings from P-II (ICARUS-Breast01) & a P-I/II breast cancer study published in The JCO (Jun 2022), which demonstrated superior activity of patritumab DXd in metastatic breast cancer pts
- In Oct 2023, Daiichi & Merck entered a global co-development & commercialization deal for patritumab DXd, ifinatamab DXd, & raludotatug DXd, with Daiichi retaining Japan rights & handling manufacturing & supply
Ref: Daiichi Sankyo | Image: Daiichi Sankyo and Merck | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
